Ehab (Adam) Ibrahim is a seasoned veteran of the pharmaceutical industry, recognized for his exceptional ability to initiate, direct, and scale the growth of pharmaceutical enterprises under his leadership. Among his many strengths, he is highly proficient in business development, supply chain optimization, and cost-effective manufacturing strategies. He is currently a leading figure in the blow–fill–seal (BFS) preservative-free market, working closely with globally recognized regulatory bodies including the FDA, the European Union, and ISO 13485 for medical devices.

During his undergraduate and graduate studies, Dr. Ibrahim focused extensively on physics, chemistry, and pharmaceutical technologies. He began his career in the pharmaceutical sector working in formulation development, pre-formulation, pharmaceutical analysis, clinical trials, and commercial manufacturing. Over more than 25 years in the industry, he has gained deep, practical insight across multiple disciplines and has become a widely respected authority in pharmaceutical development and manufacturing.

Dr. Ibrahim advanced through several high-profile executive leadership roles both in the United States and internationally. Throughout his career, he has worked extensively in the pharmaceutical and biopharmaceutical sectors, specializing in small molecules, peptides, and proteins. He has led and contributed to a wide range of organizations, including generic, branded, drug-delivery, medical device, and CDMO/CMO companies. His professional experience includes senior roles at Sandoz (Novartis), Warner-Lambert (Pfizer), Teva, Barr Laboratories, Zenith Laboratories, Zenith Gold Line, Glenwood Palisades, Akzo Specialty Chemicals, Emisphere Technologies, and ApiCross Drug Delivery.

Dr. Ibrahim has successfully developed and commercialized more than 100 specialty drug products. In recognition of his contributions, he received the Award for Technical Excellence from Emisphere Technologies for his work on insulin tablet and capsule drug-delivery systems involving proteins and peptides.

Since 2008, Dr. Ibrahim has served as Chief Executive Officer and Chief Scientific Officer of Horizon Pharmaceuticals Inc., which he founded and developed into a leading U.S.-based CDMO specializing in niche BFS aseptic filling technologies. He is a recognized expert in aseptic sterile filling using BFS technology, single-dose cost-effective delivery systems (SDDS), and sterile multi-dose preservative-free and preserved formulations.

His expertise spans sterile ophthalmic (eye drops), respiratory (inhalation), otic (ear drops), diagnostic, and injectable products. In addition, Dr. Ibrahim is highly skilled in the development of oral solid dosage forms, including tablets (extended-release, delayed-release, immediate-action, bi-layer, tri-layer, and osmotic delivery systems), capsules, liquids, emulsions, and suspensions. He is also well-versed in the conceptualization, development, production, and commercialization of rapid diagnostic test kits.